A targetable type III immune response with increase of IL-17A expressing CD4<sup>+</sup> T cells is associated with immunotherapy-induced toxicity in melanoma.

Dimitriou F, Cheng PF, Saltari A, Schaper-Gerhardt K, Staeger R, Haunerdinger V, Sella F, Tastanova A, Urban C, Dettwiler S, Mihic-Probst D, Matter CM, Michielin O, Gutzmer R, Long GV, Becher B, Levesque MP, Dummer R.

Open source

DOI
10.1038/s43018-024-00810-4
Published
2024-08-29
Container
Nat Cancer
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1038/s43018-024-00810-4,
  title = {A targetable type III immune response with increase of IL-17A expressing CD4\<sup\>+\</sup\> T cells is associated with immunotherapy-induced toxicity in melanoma.},
  author = {Dimitriou F and  Cheng PF and  Saltari A and  Schaper-Gerhardt K and  Staeger R and  Haunerdinger V and  Sella F and  Tastanova A and  Urban C and  Dettwiler S and  Mihic-Probst D and  Matter CM and  Michielin O and  Gutzmer R and  Long GV and  Becher B and  Levesque MP and  Dummer R.},
  year = {2024},
  journal = {Nat Cancer},
  doi = {10.1038/s43018-024-00810-4},
  url = {https://doi.org/10.1038/s43018-024-00810-4}
}

RIS

TY  - JOUR
TI  - A targetable type III immune response with increase of IL-17A expressing CD4<sup>+</sup> T cells is associated with immunotherapy-induced toxicity in melanoma.
AU  - Dimitriou F
AU  -  Cheng PF
AU  -  Saltari A
AU  -  Schaper-Gerhardt K
AU  -  Staeger R
AU  -  Haunerdinger V
AU  -  Sella F
AU  -  Tastanova A
AU  -  Urban C
AU  -  Dettwiler S
AU  -  Mihic-Probst D
AU  -  Matter CM
AU  -  Michielin O
AU  -  Gutzmer R
AU  -  Long GV
AU  -  Becher B
AU  -  Levesque MP
AU  -  Dummer R.
PY  - 2024
JO  - Nat Cancer
DO  - 10.1038/s43018-024-00810-4
UR  - https://doi.org/10.1038/s43018-024-00810-4
ER  - 

APA

F, D., PF, C., A, S., K, S., R, S., V, H., F, S., A, T., C, U., S, D., D, M., CM, M., O, M., R, G., GV, L., B, B., MP, L., & R., D. (2024). A targetable type III immune response with increase of IL-17A expressing CD4<sup>+</sup> T cells is associated with immunotherapy-induced toxicity in melanoma.. Nat Cancer. https://doi.org/10.1038/s43018-024-00810-4

Source records